Irsamla (Vortioxetine Hydrobromide)

Vortioxetine hydrobromide works by inhibiting the serotonin transporter, which raises serotonin levels in the brain, and by modulating several serotonin receptors (5‑HT1A agonist, 5‑HT1B partial agonist, 5‑HT3/5‑HT7 antagonist). This multimodal action enhances serotonergic neurotransmission and supports mood and cognition.

The appropriate dose of Irsamla is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerability. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety of vortioxetine hydrobromide in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare provider.

To order Irsamla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irsamla (vortioxetine) is a serotonin modulator and stimulator, offering a broader receptor profile than traditional selective serotonin reuptake inhibitors (SSRIs). This may result in additional benefits for cognition and a different side‑effect spectrum, though individual response varies and treatment choice should be individualized.

Irsamla tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Irsamla is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise instructed.

The most serious risks include the potential for serotonin syndrome, especially when combined with other serotonergic agents, and the emergence of suicidal thoughts or behaviors, particularly during early treatment or dose changes. Patients should be monitored closely for these events.

Irsamla should not be used by individuals taking monoamine oxidase inhibitors (MAOIs) or those who have had a recent MAOI therapy (within 14 days). It is also contraindicated in patients with known hypersensitivity to vortioxetine or any of its excipients.